Evidence map›Paper›PMID 27870940›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2017

Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic.

Sid E O'Bryant, Michelle M Mielke, Robert A Rissman, Simone Lista, Hugo Vanderstichele, Henrik Zetterberg, Piotr Lewczuk, Holly Posner, James Hall, Leigh Johnson and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 155 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
155citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

155 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Precision medicine for Alzheimer's disease in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. "Advances in biomarker discovery and diagnostics for alzheimer's disease".Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  19. Article
  20. Article

95 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Sid E O'BryantInstitute for Healthy Aging, University of North Texas Health Science Center, Fort Worth, TX, USA. Electronic address: sid.obryant@unthsc.edu.
Michelle M MielkeDepartment of Neurology, Mayo Clinic, Rochester, MN, USA; Department of Health Science Research, Mayo Clinic, Rochester, MN, USA.
Robert A RissmanAlzheimer's Disease Cooperative Study, Department of Neurosciences, UCSD School of Medicine, La Jolla, CA, USA.
Simone ListaAXA Research Fund and UPMC Chair, Paris, France; Department de Neurologie, Institut de la Memorie et de la Maladie d'Alzheimer (IM2A) et Institut du Cerveau et du la Moelle epiniere (ICM), Hospital de la Pitie-Salpetriere, Sorbonne Universites, Universite Pierre et Marie Curie, Paris, France.
Hugo VandersticheleADx NeuroSciences NV, Ghent, Belgium.
Henrik ZetterbergClinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gotenburg, Molndal, Sweden; UCL Institute of Neurology, London, UK.
Piotr LewczukDepartment of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen and Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany; Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Bialystok, Poland.
Holly PosnerPfizer, Inc., New York, USA.
James HallInstitute for Healthy Aging, University of North Texas Health Science Center, Fort Worth, TX, USA.
Leigh JohnsonInstitute for Healthy Aging, University of North Texas Health Science Center, Fort Worth, TX, USA.
Yiu-Lian FongJohnson & Johnson, London Innovation Center, London, UK.
Johan LuthmanNeuroscience Clinical Development, Clinical Neuroscience Eisai, Woodcliff Lake, NJ, USA.
Andreas JerominQuanterix Corporation, Lexington, MA, USA.
Richard Batrla-UtermannRoche Diagnostics International Ltd., Rotkreuz, Switzerland.
Alcibiades VillarrealCentro de Neurociencias y Unidad de Investigacion Clinica, Instituto de Investigaciones Cientificas y Servicios de Alta Tecnologia (INDICASAT AIP), Ciudad del Saber, Panama, Panama.
Gabrielle BrittonCentro de Neurociencias y Unidad de Investigacion Clinica, Instituto de Investigaciones Cientificas y Servicios de Alta Tecnologia (INDICASAT AIP), Ciudad del Saber, Panama, Panama.
Peter J SnyderDepartment of Neurology, Rhode Island Hospital and Alpert Medical School of Brown University, Providence, RI, USA.
Kim HenriksenNeurodegenerative Diseases, Nordic Bioscience Biomarkers and Research, Herlev, Denmark.
Paula GrammasGeorge and Anne Ryan Institute for Neuroscience, University of Rhode Island, RI, USA.
Veer GuptaFaculty of Health, Engineering and Sciences, Center of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia.
Ralph MartinsFaculty of Health, Engineering and Sciences, Center of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia.
Harald HampelAXA Research Fund and UPMC Chair, Paris, France; Department de Neurologie, Institut de la Memorie et de la Maladie d'Alzheimer (IM2A) et Institut du Cerveau et du la Moelle epiniere (ICM), Hospital de la Pitie-Salpetriere, Sorbonne Universites, Universite Pierre et Marie Curie, Paris, France.
Biofluid Based Biomarker Professional Interest Area

Funding

Proinflammatory Endophenotype to predict NSAID treatment response Alzheimer's trialsR01AG051848 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI LYKETSOS, CONSTANTINE G, O'BRYANT, SID E · 2016 to 2020
$3.7M
Health Disparities in Alzheimer's Disease Among Mexican AmericansR56AG054073 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI O'BRYANT, SID E · 2016 to 2016
$2.1M
Pathogenicity of neuronally-derived tau in exosomesR21AG051839 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RISSMAN, ROBERT · 2016 to 2017
$426k
NIA NIH HHS R01 AG051848NIA NIH HHS R21 AG051839NIA NIH HHS R56 AG054073
6 · The paper itself

Abstract

The last decade has seen a substantial increase in research focused on the identification of blood-based biomarkers that have utility in Alzheimer's disease (AD). Blood-based biomarkers have significant advantages of being time- and cost-efficient as well as reduced invasiveness and increased patient acceptance. Despite these advantages and increased research efforts, the field has been hampered by lack of reproducibility and an unclear path for moving basic discovery toward clinical utilization. Here we reviewed the recent literature on blood-based biomarkers in AD to provide a current state of the art. In addition, a collaborative model is proposed that leverages academic and industry strengths to facilitate the field in moving past discovery only work and toward clinical use. Key resources are provided. This new public-private partnership model is intended to circumvent the traditional handoff model and provide a clear and useful paradigm for the advancement of biomarker science in AD and other neurodegenerative diseases.

Indexed as

Cooperative BehaviorPublic-Private Sector PartnershipsAlzheimer DiseaseBiomarkersFemaleHumansMaleReproducibility of ResultsBiomarkersAlzheimer's diseaseBiomarkerBloodCerebrospinal fluidContext of useDiagnosisImaging

Identifiers

PMID27870940
PMCPMC5218961

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.